Olmesartán/Amlodipino Aurovitas (Olmesartan Medoxomil, Amlodipine)

Olmesartan/amlodipine is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension in patients who require combined RAAS inhibition and calcium‑channel blockade: provides additive blood‑pressure control.
• Hypertension in patients who are intolerant to monotherapy with either component: offers an alternative single‑pill regimen.
• Hypertension with concomitant target‑organ protection: helps reduce risk of stroke and myocardial infarction.
• Resistant hypertension as adjunct therapy: may be added when blood pressure remains uncontrolled on other agents.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Amlodipine, a dihydropyridine calcium‑channel blocker, inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination yields complementary reduction of peripheral resistance and blood‑volume‑related pressure, producing additive antihypertensive effects.

Olmesartan/amlodipine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Peripheral edema: mild swelling of ankles or feet.
• Headache: transient tension‑type headache.
• Dizziness: especially on standing.
• Flushing: warm sensation, often brief.
• Fatigue: generalized tiredness.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips or throat.
• Severe hypotension: symptomatic low blood pressure.
• Hepatic dysfunction: elevated liver enzymes.
• Renal impairment: worsening kidney function.
• Myocardial infarction: rare but reported in susceptible patients.
• Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Olmesartan/amlodipine, clinicians should consider several safety aspects.

• Renal function: assess baseline creatinine and monitor periodically.
• Hepatic function: evaluate liver enzymes before initiation.
• Electrolyte balance: watch for potassium abnormalities.
• Pregnancy: avoid use; teratogenic risk is possible.
• Elderly patients: start at lower dose and monitor for hypotension.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/amlodipine may interact with several medicines; awareness helps prevent clinically relevant events.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitor, another ARB): increased risk of hyperkalaemia and renal dysfunction.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise amlodipine levels.

Moderate Interactions (Monitor Closely)

• Diuretics: additive blood‑pressure lowering effect, risk of hypotension.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function.
• Lithium: possible increase in serum lithium concentrations.
• Simvastatin: amlodipine can increase statin exposure, raising myopathy risk.
• Alcohol: may enhance dizziness and hypotensive effects.